Eisai Slams DEA Over Delay In Scheduling Seizure Med

Law360, New York (August 19, 2013, 7:46 PM EDT) -- A U.S. unit of Japanese pharmaceutical firm Eisai Co. Ltd. launched an appeal in the D.C. Circuit on Monday to order the U.S. Drug Enforcement Administration to schedule its epilepsy drug Fycompa, citing the agency’s “egregious” delay to do so even though U.S. regulators have approved the drug.

Eisai Inc. argued in a petition to the U.S. Court of Appeals for the District of Columbia Circuit that the DEA’s delay in scheduling — a step required under the Controlled Substances Act to determine what category a drug...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.